NBIX Neurocrine Biosciences, Inc.

NASDAQ
$138.40

Neurocrine Biosciences, Inc. (NBIX) is expected to report earnings on November 3, 2026, after the market close. The consensus earnings estimate is $1.99 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -24.9% since its last earnings release on July 30, 2026.

Neurocrine Biosciences Beat Expectations, Raises Guidance
Thursday, July 30, 2026 · 4:01 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 3
Tuesday · 4:00 PM ET
Earnings Whisper
-
vs $1.99
Rev est $1.04B
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $154.60

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences Inc discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Held By 5 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.